Advertisement

Medical Device Marketing and the Ethics of Vaginal Mesh Kit Marketing

  • Roberta N. Clarke
Chapter

Abstract

The marketing of vaginal mesh kits raises ethical concerns related to the kit marketers, to the US Food and Drug Administration (FDA), and even to the surgeons who implanted them in patients. Had there been a better understanding of the marketing practices of the mesh kit manufacturers, a more informed perspective on the FDA’s clearance protocols and ability to police medical devices, and a recognition of the range of behaviors taken by surgeons whose patient outcomes did not meet expectations, thousands of patients might have been spared harm. An analysis of the ethical choices of kit manufacturers and their sales reps, often well intended but incentivized to achieve business objectives over service to the patient, combined with the uncertainties related to the causes of suboptimal patient outcomes reveals a complicated set of factors. A particularly troublesome outcome of this analysis is the recognition that surgeons in all likelihood were not fully informed regarding approval or clearance process by which these devices came to market, raising the ethical question: how are surgeons to provide this fair, impartial, and complete information to the patient for informed consent when the primary source of data for the surgeon are the medical device representatives who finds themselves challenged to act ethically?

Keywords

Ethics Marketing Informed consent Consumer behavior Primum non nocere FDA clearance vs. approval Business vs. ethical decisions 

References

  1. 1.
    Zimmerman R. Surgery under scrutiny: what went wrong with vaginal mesh [Internet]. WBUR’s Common Health Reform and Reality. 2011 Nov 4. http://commonhealth.legacy.wbur.org/2011/11/surgery-under-scrutiny-what-went-wrong-with-vaginal-mesh. Accessed 1 Mar 2018.
  2. 2.
    Gonzalez R, Fugate K, McClusky D 3rd, Ritter EM, Lederman A, Dillehay D, et al. Relationship between tissue ingrowth and mesh contraction. World J Surg. 2005;29(8):1038–43.CrossRefGoogle Scholar
  3. 3.
    Margulies RU, Lewicky-Gaupp C, Fenner DE, McGuire EJ, Clemens JQ, Delancey JO. Complications requiring reoperation following vaginal mesh kit procedures for prolapse. Am J Obstet Gynecol. 2008;199(6):678 e1–4.CrossRefGoogle Scholar
  4. 4.
    Iglesia CB, Sokol AI, Sokol ER, Kudish BI, Gutman RE, Peterson JL, Shott S. Vaginal mesh for prolapse; a randomized controlled trial. Obstet Gynecol. 2010;116(2):293–303.CrossRefGoogle Scholar
  5. 5.
    Feiner F, Maher C. Vaginal mesh contraction, definition, clinical presentation, and management. Obstet Gynecol. 2010;115(2):325–30.CrossRefGoogle Scholar
  6. 6.
    Zimmerman CW, von Theobald P, Braun NM. Exposure and erosion of vaginal meshes: etiology and treatment. In: von Theobald P, Zimmerman CW, Davila GW, editors. New techniques in genital prolapse. London: Springer; 2011. p. 217–30.CrossRefGoogle Scholar
  7. 7.
    Gomelsky A, Dmochowski RR. Vaginal mesh update. Curr Opin Urol. 2012;22:271–5.CrossRefGoogle Scholar
  8. 8.
    Chermansky CJ, Winters JC. Complications of vaginal mesh surgery. Curr Opin Urol. 2012;22(4):287–91.CrossRefGoogle Scholar
  9. 9.
    Richter LA, Carter C, Gutman RE. Current role of mesh in vaginal prolapse surgery. Curr Opin Obstet Gynecol. 2014;26(5):409–14.CrossRefGoogle Scholar
  10. 10.
    Unger CA, Abbott S, Evans JM, Jallad K, Mishra K, Karram MM, et al. Outcomes following treatment for pelvic floor mesh complications. Int Urogynecol J. 2014;25(6):745–9.CrossRefGoogle Scholar
  11. 11.
    Javadian P, O’Leary D. Vaginally placed meshes: a review of their complications, risk factors, and management. Curr Obstet Gynecol Rep. 2015;4(2):96–101.CrossRefGoogle Scholar
  12. 12.
    Manonai J, Rostaminia G, Denson L, Shobeiri SA. Clinical and ultrasonographic study of patients presenting with transvaginal mesh complications. Neurourol Urodyn. 2016;35(3):407–11.CrossRefGoogle Scholar
  13. 13.
    Javadian P, Quiroz LH, Shobeiri SA. In vivo ultrasound characteristics of vaginal mesh kit complications. Female Pelvic Med Reconstr Surg. 2017;23(2):162–7.CrossRefGoogle Scholar
  14. 14.
    Nosti PA, Iglesia CB. Medicolegal issues surrounding devices and mesh for surgical treatment of prolapse and incontinence. Clin Obstet Gynecol. 2013;56(2):221–8.CrossRefGoogle Scholar
  15. 15.
    Ray M, Sawyer A, Rothschild M, Heeler R, Strong E, Reed J. Marketing communications and the hierarchy-of-effects. In: Clarke P, editor. New models for mass communication research. Beverly Hills: Sage; 1973. p. 147–76.Google Scholar
  16. 16.
    Donabedian A. Evaluating the quality of medical care. Milbank Q. 2005;83(4):691–729.CrossRefGoogle Scholar
  17. 17.
    Macdonald JE, Beck-Dudley CL. Are deontology and teleology mutually exclusive? J Bus Ethics. 1994;13(8):615–23.CrossRefGoogle Scholar
  18. 18.
    Harris JD, Parmar BL, Wicks AC. Ethical business decisions: the lens. 2015 Jul 24 [Internet]. Darden ideas to action. University of Virginia Darden School of Business. https://ideas.darden.virginia.edu/2015/07/ethical-business-decisions-the-lens/. Accessed 2 Mar 2018.
  19. 19.
    Bazerman MH, Tenbrunsel AE. Ethical breakdowns. 2011 Apr. Harv Bus Rev [Internet]. https://hbr.org/2011/04/ethical-breakdowns. Accessed 2 Mar 2018.
  20. 20.
    Kotler P, Clarke RN. Marketing for health care organizations. Englewood Cliffs: Prentice-Hall, Inc; 1987.Google Scholar
  21. 21.
    Nelson LJ, Clark HW, Goldman RL, Schore JE. Taking the train to a world of strangers: health care marketing and ethics. Hastings Cent Rep. 1989;19(5):36–43.CrossRefGoogle Scholar
  22. 22.
    Dickinson J. Medical devices head for pharma-type public ads [Internet]. Medical Device + Diagnostic Industry (MD+DI). 2016 Feb 26. http://www.mddionline.com/blog/devicetalk/medical-devices-head-pharma-type-public-ads-02-16-16. Accessed 1 Mar 2018.
  23. 23.
    Mitka M. Direct-to-consumer advertising of medical devices under scrutiny. JAMA. 2008;300(17):1985–6.CrossRefGoogle Scholar
  24. 24.
    Beauchamp T, Childress J. Principles of biomedical ethics. 5th ed. Oxford: Oxford University Press; 2001. p. 79–80.Google Scholar
  25. 25.
    U. S. Department of Health and Human Services. Office of Disease Prevention and Health Promotion. Quick guide to health literacy; 2006 [Internet]. https://health.gov/communication/literacy/quickguide/. Accessed 1 Mar 2018.
  26. 26.
    Knifed E, Lipsman N, Mason W, Bernstein M. Patients’ perception of the informed consent process for neurooncology trials. Neuro-Oncology. 2008;10(3):348–54.CrossRefGoogle Scholar
  27. 27.
    Sher S. A framework for assessing immorally manipulative marketing tactics. J Bus Ethics. 2011;102(97):97–118.CrossRefGoogle Scholar
  28. 28.
    Lopez McHugh LLP. Product news and recalls. Litigation continues over defective Johnson & Johnson transvaginal mesh. 2017 May 24 [Internet]. http://lopezmchugh.com/2017/05/24/litigation-continues-defective-johnson-johnson-transvaginal-mesh/index.html. Accessed 2 Mar 2018.
  29. 29.
    ClassAction.com. Transvaginal mesh lawsuit settlement. Updated 2018 Mar 12 [Internet]. https://www.classaction.com/transvaginal-mesh/settlement/. Accessed 31 Mar 2018.
  30. 30.
    Smith J, Barrett S. What are 510(k) clearance and premarket approval? Device Watch 12 Apr 2008. https://www.devicewatch.org/reg/reg.shtml. Accessed 31 Mar 2018.
  31. 31.
    U.S. Food & Drug Administration. Medical devices. Recalls, corrections and removals [Internet]. https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/PostmarketRequirements/RecallsCorrectionsAndRemovals/default.htm. Accessed 3 Apr 2018.
  32. 32.
    Elkins C. Transvaginal mesh recalls & discontinued products. 2013 Apr 30 [Updated 2017 Nov 1]. [Internet]. DrugWatch. T. https://www.drugwatch.com/transvaginal-mesh/recall/. Accessed 2 Mar 2018.
  33. 33.
    Lovallo D, Kahneman D. Delusions of success: how optimism undermines executives’ decisions. 2003 Jul. Harvard Business Rev [Internet]. https://hbrorg/2003/07/delusions-of-success-how-optimism-undermines-executives-decisions. Accessed 3 Mar 2018.
  34. 34.
    Rehak J. International Herald Tribune. Tylenol made a hero of Johnson & Johnson: the recall that started them all. 2002 Mar 23. The New York Times [Internet]. http://www.nytimes.com/2002/03/23/your-money/tylenol-made-a-hero-of-johnson-johnson-the-recall-that-started.html. Accessed 2 Mar 2018.
  35. 35.
    Krugman P. The conscience of a liberal. The greatness of Keynes... 2008 Nov 20 [Internet]. The New York Times. https://krugman.blogs.nytimes.com/2008/11/30/the-greatness-of-keynes/. Accessed 3 Mar 2018.
  36. 36.
    Auto Editors of Consumer Guide “1971–1980 Ford Pinto”. 9 Aug 2007. HowStuffWorks.com. InfoSpace Holdings LLC. https://auto.howstuffworks.com/1971-1980-ford-pinto.htm. Accessed 2 Mar 2018.
  37. 37.
    Elkins C. Transvaginal mesh verdicts and settlements [Internet]. Drugwatch. 2013 Sept 25 [Last updated 2017 Dec 22]. https://www.drugwatch.com/transvaginal-mesh/verdict-settlement/. Accessed 2 Mar 2018.
  38. 38.
    Bronstad A. J&J looking to rebound from series of megaverdicts. 2016 Dec 7. Nat Law J [Internet]. http://www.nationallawjournal.com/id=1202774155233/JampJ-Looking-to-Rebound-From-Series-of-Megaverdicts. Accessed 19 Jul 2017.
  39. 39.
    Mesh Medical Device News Desk. Kavaler expert witness for J&J on stand in Beltz mesh trial. 2017 May 17 [Internet]. Sundown Legal Marketing. Available from: http://www.meshmedicaldevicenewsdesk.com/kavaler-expert-witness-jj-stand-beltz-mesh-trial/. Accessed 2 Mar 2018.
  40. 40.
    O’Connor B, Pollner F, Fugh-Berman A. Salespeople in the surgical suite: relationships between surgeons and medical device representatives. PLoS One. 2016;11(8):e0158510.CrossRefGoogle Scholar
  41. 41.
    Rabin RC. Salesmen in the surgical suite. 2013 Mar 25. The New York Times [Internet]. http://www.nytimes.com/2013/03/26/health/salesmen-in-the-surgical-suite.html. Accessed 2 Mar 2018.
  42. 42.
    Boodman SG. Why is that salesman in the operating room for your knee replacement? 2016 Nov 24. The Washington Post [Internet]. https://www.washingtonpost.com/national/health-science/why-is-that-salesperson-in-the-operating-room-for-your-knee-replacement/2016/11/14/ab8172fa-78e6-11e6-beac-57a4a412e93a_story.html?utm_term=.36124727f876. Accessed 2 Mar 2018.
  43. 43.
    Bontemps B. 510(k) vs PMA: do you know the difference? 2016 Dec 21 [Internet]. Hayes Evidence Blog. http://blog.hayesinc.com/blog-what-is-the-510k-exemption-process-for-devices. Accessed 2 Mar 2018.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Health Care Management Program, Questrom School of Business, Emeritus Boston UniversityBostonUSA

Personalised recommendations